WASHINGTON — White House officials say U.S. producers of vaccine materials and ingredients will no longer have to prioritize orders from three companies working on COVID-19 shots.

The change is expected to ease global shortages of key vaccine materials for overseas companies and governments.

Officials say the government is dropping its use of the Defense Production Act to prioritize supply orders from AstraZeneca, Novavax and Sanofi. Those three companies have not yet won U.S. authorization for their COVID-19 shots, despite receiving funding from the federal government for development and manufacturing.

Administration officials say the U.S. now has enough vaccines to protect all Americans. President Joe Biden has faced increasing pressure to make more U.S. vaccines and supplies available to struggling countries.